Skip to main content
Top
Published in: International Journal of Hematology 2/2010

01-03-2010 | Letter to the Editor

Monitoring plasma heparin concentration in a patient with antiphospholipid syndrome

Authors: Tohru Inaba, Yoichi Yuki, Sayuri Nishino, Shuhei Komatsu, Hidetaka Ishino, Hajime Tsuji, Naohisa Fujita

Published in: International Journal of Hematology | Issue 2/2010

Login to get access

Excerpt

Antiphospholipid syndrome (APS) is an acquired thrombophilia characterized by the occurrence of arterial and venous events as well as recurrent miscarriages [1, 2]. In the revised classification criteria for APS, lupus anticoagulant (LAC), anti-cardiolipin antibody (aCL), and anti-β2 glycoprotein-I antibody (aβ2GPI) have been utilized as laboratory criteria [1]. Concerning the LAC assay, prolongation of a phospholipid-dependent clotting time such as activated partial thromboplastin time (aPTT) has been commonly used as a screening test [3]. Once patients are diagnosed as having APS, they are recommended to receive prolonged antithrombotic therapy, especially with warfarin [4, 5]. We encountered a patient with APS who could not receive oral warfarin because of malabsorption, and it was also difficult to perform conventional therapeutic monitoring of the heparin dosage using aPTT because of the baseline prolongation of aPTT due to LAC. …
Literature
1.
go back to reference Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.CrossRefPubMed Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.CrossRefPubMed
2.
go back to reference Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood. 2009;113:985–94.CrossRefPubMed Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood. 2009;113:985–94.CrossRefPubMed
3.
go back to reference Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Aticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost. 1995;74:1597–603.PubMed Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Aticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost. 1995;74:1597–603.PubMed
4.
go back to reference Khamashta MA, Cuadrado MA, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombus in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993–7.CrossRefPubMed Khamashta MA, Cuadrado MA, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombus in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993–7.CrossRefPubMed
5.
go back to reference Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57:1487–95.CrossRefPubMed Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57:1487–95.CrossRefPubMed
6.
go back to reference Wittkowsky AK, Kino KJ. Heparin monitoring in acute thrombosis associated with antiphospholipid antibody syndrome. Pharmacotherapy. 1995;15:517–21.PubMed Wittkowsky AK, Kino KJ. Heparin monitoring in acute thrombosis associated with antiphospholipid antibody syndrome. Pharmacotherapy. 1995;15:517–21.PubMed
Metadata
Title
Monitoring plasma heparin concentration in a patient with antiphospholipid syndrome
Authors
Tohru Inaba
Yoichi Yuki
Sayuri Nishino
Shuhei Komatsu
Hidetaka Ishino
Hajime Tsuji
Naohisa Fujita
Publication date
01-03-2010
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0508-x

Other articles of this Issue 2/2010

International Journal of Hematology 2/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine